| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Hamilton Regional Cancer Centre, Hamilton, Ontario, L8V 5C2 Canada [S. Si., S. Sa., S. Su, S. P., G. S.], and Department of Urology, University of California Los Angeles, Los Angeles, California 90095 [A. B.]
The androgen-sensitive LNCaP prostate cancer cell line is less invasive than hormone-insensitive lines. CL1, an aggressive, hormone-insensitive LNCaP subline derived by continuous passaging in hormone-depleted medium, was compared with the parental cell line by cDNA microarray analysis. The gene coding for the intermediate filament protein vimentin was found to be highly up-regulated in the CL1 subline. This difference was confirmed by Northern and Western blots and visualized by immunofluorescence microscopy. To assess the contribution of vimentin to the invasive phenotype, LNCaP cells were stably transfected to overexpress vimentin, and the CL1 cells were transfected with vimentin antisense construct. The invasiveness of the transfected cells was tested using an in vitro invasion assay. We were able to demonstrate that decreasing vimentin expression in the constitutively vimentin-expressing CL1 cells led to a significant decrease in their invasiveness but that forcing expression of vimentin in the LNCaP cells did not augment their invasiveness. These findings imply that vimentin expression contributes to the invasive phenotype but cannot confer it alone.
This article has been cited by other articles:
![]() |
S. Chu, H. Xu, T. J. Ferro, and P. X. Rivera Poly(ADP-ribose) polymerase-1 regulates vimentin expression in lung cancer cells Am J Physiol Lung Cell Mol Physiol, November 1, 2007; 293(5): L1127 - L1134. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Welsh, P. T. K. Saunders, and R. M. Sharpe The Critical Time Window for Androgen-Dependent Development of the Wolffian Duct in the Rat Endocrinology, July 1, 2007; 148(7): 3185 - 3195. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Jungert, A. Buck, G. v. Wichert, G. Adler, A. Konig, M. Buchholz, T. M. Gress, and V. Ellenrieder Sp1 Is Required for Transforming Growth Factor-{beta}-Induced Mesenchymal Transition and Migration in Pancreatic Cancer Cells Cancer Res., February 15, 2007; 67(4): 1563 - 1570. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. van Beijnum, R. P. Dings, E. van der Linden, B. M. M. Zwaans, F. C. S. Ramaekers, K. H. Mayo, and A. W. Griffioen Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature Blood, October 1, 2006; 108(7): 2339 - 2348. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Rohn, A. Reitz, A. Paschen, X. D. Nguyen, D. Schadendorf, A. B. Vogt, and H. Kropshofer A Novel Strategy for the Discovery of MHC Class II-Restricted Tumor Antigens: Identification of a Melanotransferrin Helper T-Cell Epitope Cancer Res., November 1, 2005; 65(21): 10068 - 10078. [Abstract] [Full Text] [PDF] |
||||
![]() |
T L Veveris-Lowe, M G Lawrence, R L Collard, L Bui, A C Herington, D L Nicol, and J A Clements Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells Endocr. Relat. Cancer, September 1, 2005; 12(3): 631 - 643. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. K. Kwok, M.-T. Ling, T.-W. Lee, T. C.M. Lau, C. Zhou, X. Zhang, C. W. Chua, K. W. Chan, F. L. Chan, C. Glackin, et al. Up-Regulation of TWIST in Prostate Cancer and Its Implication as a Therapeutic Target Cancer Res., June 15, 2005; 65(12): 5153 - 5162. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K Oosterhoff, J A. Grootegoed, and L. J Blok Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling Endocr. Relat. Cancer, March 1, 2005; 12(1): 135 - 148. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-P. Lim, C. Y. Wong, L. L. Ooi, B. J. Druker, and R. J. Epstein Selective Tyrosine Hyperphosphorylation of Cytoskeletal and Stress Proteins in Primary Human Breast Cancers: Implications for Adjuvant Use of Kinase-Inhibitory Drugs Clin. Cancer Res., June 15, 2004; 10(12): 3980 - 3987. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |